A National Securities Arbitration & Investment Fraud Law Firm

Facebook IconTwitter IconLinkedIn IconJustia IconFeed Icon

Published on:

Nabriva Therapeutics (NBRV) Subject Of A Class Action Lawsuit

Nabriva Therapeutics (NBRV), a publicly-traded biopharmaceutical company, is the subject of a class action lawsuit filed on behalf of shareholders who lost money investing in the company. Investors who purchased shares between November 1, 2018 and April 30, 2019 (the class period) may be eligible to participate in the lawsuit.Nabriva Therapeutics (NBRV), a publicly-traded biopharmaceutical company, is the subject of a class action lawsuit filed on behalf of shareholders who lost money investing in the company.

Nabriva Class Period And Lead Plaintiff Deadline

Investors who purchased shares between November 1, 2018 and April 30, 2019 (the class period) may be eligible to participate in the lawsuit.

The deadline to apply to the court to be appointed as lead plaintiff, also called class representative, is July 8, 2019.

Nabriva Therapeutics is engaged in developing anti-infective drugs to treat serious infections. One drug they are trying to bring to market is an antibiotic called CONTEPO.

CONTEPO Manufacturing Deficiencies

The class action lawsuit alleges that, during the class period, Nabriva made false and misleading statements or didn’t disclose that the company’s manufacturers weren’t using acceptable manufacturing practices and that because of the manufacturing deficiencies CONTEPO wasn’t likely to be approved by the FDA.

On April 30, 2019, Nabriva revealed that the Food and Drug Administration (FDA) would not be approving its new drug application for CONTEPO because of “issues related to facility inspections and manufacturing deficiencies at one of Nabriva’s contract manufacturers.”

On May 1, 2019, Nabriva’s stock price closed down 27.42%, causing significant loss to shareholders.

Leerink Partners LLC and RBC Capital Markets, LLC were joint book-running managers for Nabriva’s initial public offering in 2015, which raised more than $92 million.

Recovering Money Lost With Nabriva Therapeutics (NBRV) Stock

If you suffered losses with Nabriva Therapeutics, you may be able to recover some of your losses by participating in the lawsuit.

Silver Law Group represents the interests of investors who have been the victims of investment fraud. Our attorneys represent investors in class actions against issuers in state or federal court and investors in securities arbitration claims against Wall Street firms for stockbroker misconduct. Scott Silver is the chairman of the Securities and Financial Fraud Group of the American Association of Justice and represents investors nationwide in securities investment fraud cases. Please contact Scott Silver of the Silver Law Group for a free consultation at ssilver@silverlaw.com or toll free at (800) 975-4345.

 

Contact Information